Thaddeus Nowinski, MD
Ophthalmology · Lansdale, PANPI 1578561957
Payments from drug & device makers
Across 53 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$157
- Bausch & Lomb, A Division Of Bausch Health US, LLC$154
- Sun Pharmaceutical Industries Inc.$131
- Amgen$113
- Alcon$98
- Oyster Point Pharma, Inc.$55
- plus $308 from 11 others
What the payments were for
- Food & beverage$99998%
- Gifts$172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $157 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $154 |
| Sun Pharmaceutical Industries Inc. | 6 | $131 |
| Amgen | 8 | $113 |
| Alcon | 5 | $98 |
| Oyster Point Pharma, Inc. | 3 | $55 |
| Novartis | 3 | $52 |
| Dompe US, Inc. | 2 | $48 |
| Shire North American Group Inc | 2 | $47 |
| Carl Zeiss Meditec, Inc. | 2 | $36 |
| Carl Zeiss Meditec USA, Inc. | 1 | $28 |
| Bausch & Lomb Americas Inc. | 1 | $25 |
| Glaukos Corporation | 1 | $17 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
| Biotissue Holdings Inc. | 1 | $10 |
How this compares
$1,016 in reported general payments places this provider in the 40th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 13 | $12,163 |
| Dexamethasone Sodium Phosphate | 12 | $551 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 43 | $508 |
| ErythromycinErythromycin Base | 28 | $407 |
| Latanoprost | 33 | $156 |
| Doxycycline Hyclate | 14 | $122 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Lansdale
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.